DTx is growing rapidly in China and requires a clear strategy for commercialization.
A global pharma company would like to assess the potential monetization options for its innovative clinical-stage DTx product, consisting of a digital system with a Bluetooth sensor, an AI algorithm for prognosis, and databases for tracking and monitoring real-world outcomes.
Our team helped the client articulate key value drivers of the DTx and developed a robust strategy with easy wins.
We first developed a China access framework for DTx, outlining value propositions and monetization options for DTx as a whole and its different components on a standalone basis.
Next, we analyzed relevant analog case studies in DTx in China and summarized key takeaways and implications for the client’s product.
We then conferred with payers and potential partners on DTx value perceptions, business opportunities, and monetization strategy and summarized value propositions including better compliance with patients and caregivers, better outcomes in real-world settings, and better socioeconomics for payers.
Our work helped the client develop a forward-looking and actionable strategy for its cutting-edge DTx technology on the Chinese market,
including key value propositions and messages for DTx to highlight with key stakeholders.
Kontakt
Nehmen Sie Kontakt zu uns auf, unser Team berät Sie gerne.